MX2023005563A - Profilaxis y tratamiento del angioedema. - Google Patents

Profilaxis y tratamiento del angioedema.

Info

Publication number
MX2023005563A
MX2023005563A MX2023005563A MX2023005563A MX2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A
Authority
MX
Mexico
Prior art keywords
treatment
angioedema
human patient
alleviate
symptoms
Prior art date
Application number
MX2023005563A
Other languages
English (en)
Spanish (es)
Inventor
Peng Lu
Anne Lesage
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of MX2023005563A publication Critical patent/MX2023005563A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023005563A 2020-11-12 2021-11-12 Profilaxis y tratamiento del angioedema. MX2023005563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
MX2023005563A true MX2023005563A (es) 2023-09-11

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005563A MX2023005563A (es) 2020-11-12 2021-11-12 Profilaxis y tratamiento del angioedema.

Country Status (12)

Country Link
US (1) US20230338358A1 (https=)
EP (1) EP4243824B1 (https=)
JP (1) JP2023549849A (https=)
KR (1) KR20230107269A (https=)
CN (1) CN116685353A (https=)
AU (1) AU2021376885A1 (https=)
CA (1) CA3198246A1 (https=)
ES (1) ES3061585T3 (https=)
IL (1) IL302887A (https=)
MX (1) MX2023005563A (https=)
WO (1) WO2022101395A1 (https=)
ZA (1) ZA202305122B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062067T3 (en) * 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
AR113839A1 (es) * 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
EP4243824B1 (en) 2025-12-24
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
ZA202305122B (en) 2024-08-28
CN116685353A (zh) 2023-09-01
CA3198246A1 (en) 2022-05-19
IL302887A (en) 2023-07-01
KR20230107269A (ko) 2023-07-14
EP4243824A1 (en) 2023-09-20
AU2021376885A1 (en) 2023-06-08
US20230338358A1 (en) 2023-10-26
JP2023549849A (ja) 2023-11-29
EP4243824C0 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
ZA202305122B (en) Prophylaxis and treatment of angioedema
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
ZA202310050B (en) Pharmaceutical composition for preventing or treating fibrosis
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4647125A3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
WO2021007314A3 (en) Treatment of cancer
MX2022015760A (es) Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.
MX2022012135A (es) Métodos para tratar la enfermedad de coronavirus de 2019.
MX2025000673A (es) Metodos de administracion de nalbufina
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
MX2008016520A (es) Medicamentos.
MX2025007194A (es) Antagonistas del receptor 1 del acido lisofosfatidico (lpa1) para el tratamiento de la enfermedad pulmonar intersticial
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
PH12021550134A1 (en) Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
WO2022048618A8 (en) Methods to treat inflammatory bowel disease
ZA202210474B (en) Methods of treating sars-cov-2 infections
WO2022177968A8 (en) Therapeutic methods
MX2011013541A (es) Agente terapeutico para la hipertension o de la presion sanguinea normal elevada.